Last reviewed · How we verify
A Study of LM-350 in Subjects With Advanced Solid Tumours
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Details
| Lead sponsor | LaNova Medicines Limited |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | RECRUITING |
| Enrolment | 80 |
| Start date | Thu Aug 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Jun 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Malignant Tumors
Interventions
- LM-350 for injection
Countries
China, Australia